Xtandi seeks first-line status

Share this article:

The FDA gave Medivation and Astellas a boost by giving priority review to the partners' application to expand the prostate cancer drug's indication to include first-line status.

The drug is currently indicated for metastatic castration-resistant prostate cancer patients who have previously undergone chemotherapy and was approved in 2012.

PM Live notes that a pre-chemo indication will allow Medivation to provide early treatment competition for Janssen's prostate cancer drug Zytiga, which lassoed the pre-chemo approval in July 2013.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.